NCT03482570 is a clinical trial of ActiGraph in Malignant Pleural Effusion, sponsored by The University of Hong Kong.

Who is sponsoring NCT03482570?

NCT03482570 is sponsored by The University of Hong Kong.

What drugs are being tested in NCT03482570?

Interventions in NCT03482570: ActiGraph.

What condition does NCT03482570 study?

NCT03482570 studies Malignant Pleural Effusion.

Is NCT03482570 still recruiting?

NCT03482570 is currently status unknown. Last updated 2 April 2018.

Last reviewed 2018-04-02 · How we verify

NCT03482570

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Activity Behaviours in Patients With Malignant Pleural Effusion

Status unknown Last updated 2 April 2018

What this trial tests

trial testing ActiGraph in Malignant Pleural Effusion in 200 participants. Status unknown.

Timeline

31 January 2018

Primary endpoint
31 December 2019

31 December 2020

Quick facts

Lead sponsor	The University of Hong Kong
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	31 January 2018
Primary completion	31 December 2019
Estimated completion	31 December 2020
Sites	1 location across Hong Kong

Drugs / interventions tested

ActiGraph

Conditions studied

Malignant Pleural Effusion — all drugs for Malignant Pleural Effusion →

Sponsor

The University of Hong Kong

Who can join

18 and older, any sex, with Malignant Pleural Effusion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to objectively assess activity behaviours (i.e., physical activity and sedentary behaviour) in patients with malignant pleural effusion. First, we aim to describe the physical activity and sedentary behavior of patients with MPE in Hong Kong. Secondarily, we aim to assess the relationships between activity behaviours and survival, quality of life, and respiratory symptoms e.g. shortness of breath.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Malignant Pleural Effusion

Currently open trials in the same condition.

NCT06421610 — OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion. · Phase 1 · recruiting
NCT05620329 — UNC Pleural Fluid Registry · recruiting

Other The University of Hong Kong trials

Trials by the same sponsor.

NCT05981430 — Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae · NA · not yet recruiting
NCT07478757 — Assessing the Effectiveness of Low-Dose Computed Tomography in Lung Cancer Screening for High-Risk Smokers: A Randomized · NA · not yet recruiting
NCT07448649 — Chatbot-Assisted Advance Care Planning Education for Family Members · NA · not yet recruiting
NCT07484932 — TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer · NA · not yet recruiting
NCT07531589 — BrainLive Connect: Non-professional Delivered CST for People Living With Dementia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03482570 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Hong Kong
Last refreshed: 2 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03482570.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing